Back

Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy for cardiovascular risk Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Chen Gurevitz

Rabin Medical Centre, Petah Tikva (Israel)

6 More presentations in this session

Presentation thumbnail
Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide
Professor G. Fazio (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
Semaglutide demonstrates favorable safety profile with 43% reduction in serious adverse events in adults with established ASCVD: a systematic review and meta-analysis of randomized controlled trials
Doctor V. Purewal (Scottsdale, US)
Abstract Slides Video
Presentation thumbnail
Effects of hybrid closed-loop systems and SGLT2i on myocardial deformation and vascular function in type 1 diabetics
Doctor K. Katogiannis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Prognostic outcomes of SGLT2 inhibitors versus metformin in patients with type 2 diabetes and acute myocardial infarction
Doctor H. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Early tirzepatide after kidney transplantation in diabetes is associated with lower cardiovascular events and graft failure: a multinational target trial emulation
Miss F. Lemmer (Luebeck, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy for cardiovascular risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 Analogues and cardiovascular risk reduction in adults with obesity and elevated CRP: a real-world matched cohort study
29 August 2026
thumbnail
Congress Presentation
All diabetic patients should be treated with GLP1 and/or GIP agonists.
29 August 2022
thumbnail
Congress Presentation
Cardiovascular outcomes of oral versus injectable semaglutide: a propensity-matched real-world cohort study
28 August 2026
thumbnail
Congress Presentation
Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources